Therapeutic Advances in Multiple Sclerosis

Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system that causes significant disability and healthcare burden. The treatment of MS has evolved over the past three decades with development of new, high efficacy disease modifying therapies targeting various mechanisms...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in neurology Vol. 13; p. 824926
Main Authors: Yang, Jennifer H., Rempe, Torge, Whitmire, Natalie, Dunn-Pirio, Anastasie, Graves, Jennifer S.
Format: Journal Article
Language:English
Published: Frontiers Media S.A 03.06.2022
Subjects:
demyelination
disease modifying therapy
multiple sclerosis
neurodegeneration
Neurology
review
ISSN:1664-2295, 1664-2295
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system that causes significant disability and healthcare burden. The treatment of MS has evolved over the past three decades with development of new, high efficacy disease modifying therapies targeting various mechanisms including immune modulation, immune cell suppression or depletion and enhanced immune cell sequestration. Emerging therapies include CNS-penetrant Bruton's tyrosine kinase inhibitors and autologous hematopoietic stem cell transplantation as well as therapies aimed at remyelination or neuroprotection. Therapy development for progressive MS has been more challenging with limited efficacy of current approved agents for inactive disease and older patients with MS. The aim of this review is to provide a broad overview of the current therapeutic landscape for MS.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Edited by: Robert Weissert, University of Regensburg, Germany
Reviewed by: Vincent Van Pesch, Catholic University of Louvain, Belgium; Emanuele D'Amico, University of Catania, Italy
This article was submitted to Multiple Sclerosis and Neuroimmunology, a section of the journal Frontiers in Neurology
ISSN:1664-2295
1664-2295
DOI:10.3389/fneur.2022.824926